SLC5A2 and steatosis: Liu et al. showed in mice that a treatment with the SGLT2 inhibitor dapagliflozin led to a reduced steatosis score and reduced expression of SREBP1c accordingly, possibly mediated by the activation of adenosine monophosphate-activated protein kinase (AMPK) phosphorylation and inhibition of the mammalian target of rapamycin (mTOR) phosphorylation pathways [59].